ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

VTVT vTv Therapeutics Inc

26.965
1.20 (4.64%)
Apr 26 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 3,777
Bid Price 8.50
Ask Price 30.00
News -
Day High 26.965

Low
7.38

52 Week Range

High
39.60

Day Low 24.80
Share Name Share Symbol Market Stock Type
vTv Therapeutics Inc VTVT NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
1.20 4.64% 26.965 19:00:00
Open Price Low Price High Price Close Price Previous Close
25.89 24.80 26.965 26.965 25.77
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
263 3,777 US$ 26.26 US$ 99,177 - 7.38 - 39.60
Last Trade Type Quantity Price Currency
15:15:57 formt 1,015 US$ 26.00 USD

vTv Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
US$ 81.17M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

vTv Therapeutics News

Date Time Source News Article
3/19/202407:30PR Newswire (US)CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA..
3/13/202407:00GlobeNewswire Inc.vTv Therapeutics Announces 2023 Fourth Quarter and Full Year..
3/07/202415:47Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of..
3/05/202418:52Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial..
3/05/202407:04Edgar (US Regulatory)Form 8-K - Current report
3/04/202407:00GlobeNewswire Inc.vTv Therapeutics Announces FDA Submission for First Phase 3..
3/01/202407:00GlobeNewswire Inc.vTv Therapeutics to Participate at the TD Cowen 44th Annual..
2/28/202408:26Edgar (US Regulatory)Form 8-K - Current report
2/28/202408:14Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
2/28/202407:08Edgar (US Regulatory)Form 8-K - Current report
2/28/202407:00GlobeNewswire Inc.vTv Therapeutics Announces $51 Million Private Placement..
2/22/202415:00PR Newswire (US)CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO &..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No VTVT Message Board. Create One! See More Posts on VTVT Message Board See More Message Board Posts

Historical VTVT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week24.7526.96523.8124.973,0382.228.95%
1 Month23.5426.96523.0024.915,9413.4314.55%
3 Months8.3630.998.1017.0172,97718.61222.55%
6 Months17.50830.997.3815.2162,3359.4654.02%
1 Year28.8039.607.3824.63110,050-1.84-6.37%
3 Years101.20115.207.3862.22475,392-74.24-73.35%
5 Years52.80205.207.3897.48953,664-25.84-48.93%

vTv Therapeutics Description

vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Your Recent History

Delayed Upgrade Clock